RED BANK, N.J., May 27, 2021 /PRNewswire/ -- Provention Bio,
Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to
intercepting and preventing immune-mediated disease, today
announced that Nasdaq has halted trading of the Company's common
stock.
The U.S. Food and Drug Administration (FDA) Endocrinologic and
Metabolic Drugs Advisory Committee is meeting today to discuss the
Biologics License Application (BLA) for teplizumab for the delay of
clinical type 1 diabetes (T1D) in at-risk individuals. The Advisory
Committee meeting is scheduled to start at 9:00 a.m. ET. The meeting can be accessed at:
https://investors.proventionbio.com/events.
About Provention Bio, Inc.:
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical
company focused on advancing the development of investigational
therapies that may intercept and prevent debilitating and
life-threatening immune-mediated disease. The BLA for teplizumab,
its lead investigational drug candidate, for the delay of clinical
T1D in at-risk individuals, has been filed by the FDA. The
Company's pipeline includes additional clinical-stage product
candidates that have demonstrated in pre-clinical or clinical
studies proof-of-mechanism and/or proof-of-concept in other
autoimmune diseases, including celiac disease and lupus. Visit
www.ProventionBio.com for more information and follow us on
Twitter: @ProventionBio.
Internet Posting of Information:
Provention Bio, Inc. uses its
website, www.proventionbio.com, as a means of disclosing
material nonpublic information and for complying with its
disclosure obligations under Regulation FD. Such disclosures will
be included on the Company's website in the "News" section.
Accordingly, investors should monitor this portion of the Company's
website, in addition to following its press
releases, SEC filings and public conference calls and
webcasts.
Forward Looking Statements:
Certain statements in this press release are forward-looking,
including but not limited to, statements relating to the upcoming
Advisory Committee meeting and the potential therapeutic effects of
our investigational therapies. These forward-looking statements are
based on the Company's current expectations and actual results
could differ materially. As with any pharmaceutical under
development, there are significant risks in the development,
regulatory approval and commercialization of new products, and
there are a number of factors that could cause actual events to
differ materially from those indicated by such forward-looking
statements. These factors include, but are not limited to, the
risks listed under "Risk Factors" in the Company's quarterly report
on Form 10-Q for the quarter ended March 31, 2021 and any
subsequent filings with the Securities and Exchange Commission.
Provention does not undertake an obligation to update or revise any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by
applicable law. The information set forth herein speaks only as of
the date hereof.
Investor Contact:
Robert
Doody, VP of Investor Relations
rdoody@proventionbio.com
484-639-7235
Media Contact:
Lori Rosen, LDR Communications
lori@ldrcommunications.com
917-553-6808
View original content to download
multimedia:http://www.prnewswire.com/news-releases/provention-bio-stock-trading-halted-today-301300109.html
SOURCE Provention Bio, Inc.